Drug products: Azathioprin 1A Farma, Azathioprin Actavis, Azathioprin Orifarm, Azathioprine, Azathioprine medac, Azatioprin Mylan, Imuran, Imuran®, Imurel®
ATC code: L04AX01
Substances: azathioprine, azathioprine sodium
Studies have shown that men with Crohn disease treated with azathioprine had lower relapse rates than women.
A pediatric study has shown that girls with inflammatory bowel disease treated with azathioprine had a higher ratio of the potentially toxic metabolites 6-MeMPN and 6-TGN than boys. This could increase the risk of liver and blood reactions. Therapeutic drug monitoring of azathioprine and the metabolites may be of particular importance in girls.
Azathioprine is a prodrug to 6-mercaptopurine (6-MP), which has a major active metabolite, 6-TGN, and two inactive metabolites, 6-thiouracil and 6-methyl-mercaptourine (6-MeMPN). High 6-TGN levels are responsible for myelotoxicity, while high levels of 6-MeMPN are associated with hepatotoxicity. A retrospective study has explored the weight-based dosage of azathioprine and the metabolite concentrations in pediatric patients with inflammatory bowel disease (45 boys, 41 girls). Multivariate analysis showed that girls had 36.3% higher 6-MeMPN/6-TGN ratio than boys . No other studies with a clinically relevant sex analysis regarding the pharmacokinetics of azathioprine have been found.
Asian patients with Crohn disease might require lower doses of azathioprine than European patients. The efficacy of low-dose azathioprine (<1.0 mg/kg) in maintaining remission of Crohn disease in Chinese patients has been analyzed in a retrospective study of medical records (54 men, 23 women). The doses of azathioprine were adjusted according to efficacy and tolerance. A dose of <1.0 mg/kg azathioprine was more common in men . A possible explanation could be that higher rates of relapse have been observed in female patients with Crohn disease [3, 4], and their doses have been escalated.
Long-term follow-up of patients with Crohn disease treated with azathioprine or 6-mercaptopurine has been evaluated retrospectively (68 men, 89 women). Patients were treated with azathioprine or 6-mercaptopurine for >6 months and were in clinical remission. Women had a higher risk of relapse during the drug treatment (risk ratio 2.3; 95% CI: 1.0-5.1), while men had higher risk after drug withdrawal (risk ratio 5.2; 95%CI 2.2-12.0). Therefore, the authors assumed that patients who received the greatest benefit from the drug (i.e. men) were also more affected by drug withdrawal . The better outcome in men with Crohn disease was also found in another study of patients with inflammatory bowel disease. Patients had been treated with azathioprine for >6 months .In some countries, azathioprine is used in monotherapy for severe atopic dermatitis in adult and pediatric patients. A study has reviewed the clinical efficacy of azathioprine in children with atopic dermatitis (9 boys, 8 girls; mean age 16.1 years). At 3 months, there were no differences in efficacy between boys and girls. At 6 months, girls had lower disease activity score than boys (28.4 vs. 46.8). The reason for this sex differences is unclear .In a double-blind controlled trial, multiple sclerosis patients (11 men, 19 women) were given prednisolone and azathioprine (3 mg/kg per day) for 15 months. Number of relapses during the study period was lower among patients receiving treatment and among women. However, the authors assumed that the results were more striking in women due to the small number of treated men .
A retrospective study has explored the weight-based dosage of azathioprine and the metabolite concentrations in pediatric patients with inflammatory bowel disease (45 boys, 41 girls). Multivariate analysis showed that girls had 36.3% higher 6-MeMPN/6-TGN ratio than boys. This might mean that girls develop azathioprine-induced hepatotoxicity and myelotoxicity more readily than boys. Therefore, the authors suggest that monitoring of drug concentrations are of high importance in azathioprine-treated girls with inflammatory bowel disease .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2015-06-22
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson